BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22079477)

  • 1. Cyclic nucleotide phosphodiesterases: critical modulators of endocrine, metabolic, and cardiovascular function and appealing therapeutic targets.
    Manganiello V
    Curr Opin Pharmacol; 2011 Dec; 11(6):646-8. PubMed ID: 22079477
    [No Abstract]   [Full Text] [Related]  

  • 2. PDE inhibitors: a new approach to treat metabolic syndrome?
    Lugnier C
    Curr Opin Pharmacol; 2011 Dec; 11(6):698-706. PubMed ID: 22018840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphodiesterases and regulation of female reproductive function.
    Conti M
    Curr Opin Pharmacol; 2011 Dec; 11(6):665-9. PubMed ID: 22019564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
    Levy I; Horvath A; Azevedo M; de Alexandre RB; Stratakis CA
    Curr Opin Pharmacol; 2011 Dec; 11(6):689-97. PubMed ID: 22047791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
    Medvedeva MV
    Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents.
    Murray KJ; England PJ
    Biochem Soc Trans; 1992 May; 20(2):460-4. PubMed ID: 1327922
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on the soluble phosphodiesterases of chicken gizzard smooth muscle.
    Birnbaum RJ; Head JF
    Biochem J; 1983 Dec; 215(3):627-36. PubMed ID: 6318728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic nucleotide phosphodiesterase activities of the embryonic chick ovary.
    Teng CT; Buchler B; Teng CS
    Gen Comp Endocrinol; 1981 Aug; 44(4):409-17. PubMed ID: 6167486
    [No Abstract]   [Full Text] [Related]  

  • 11. Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro.
    Truss MC; Uckert S; Stief CG; Schulz-Knappe P; Hess R; Forssmann WG; Jonas U
    Urology; 1995 May; 45(5):893-901. PubMed ID: 7747383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma.
    Nicholson CD; Shahid M
    Pulm Pharmacol; 1994 Feb; 7(1):1-17. PubMed ID: 8003849
    [No Abstract]   [Full Text] [Related]  

  • 13. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats.
    Sharma RV; Bhalla RC
    Biochim Biophys Acta; 1978 Oct; 526(2):479-88. PubMed ID: 214127
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.
    Torphy TJ; Cieslinski LB
    Mol Pharmacol; 1990 Feb; 37(2):206-14. PubMed ID: 2154670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments.
    Jackson BA; Edwards RM; Dousa TP
    Kidney Int; 1980 Oct; 18(4):512-8. PubMed ID: 6164816
    [No Abstract]   [Full Text] [Related]  

  • 17. Cyclic nucleotide phosphodiesterase assay technology.
    MacKenzie SJ; Hastings SF; Wells C
    Curr Protoc Pharmacol; 2010 Jun; Chapter 3():Unit 3.12. PubMed ID: 22294369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myofibrillar bound cyclic nucleotide phosphodiesterase in heart and skeletal muscle.
    Worby A; Mensah LM; Murray KJ
    Biochem Soc Trans; 1992 May; 20(2):129S. PubMed ID: 1327896
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase of normal and leukemic lymphocytes. Kinetic properties and selective alteration of the activity of the multiple molecular forms.
    Hait WN; Weiss B
    Mol Pharmacol; 1979 Nov; 16(3):851-64. PubMed ID: 231197
    [No Abstract]   [Full Text] [Related]  

  • 20. Characteristics of the cyclic nucleotide phosphodiesterases in a transplantable pheochromocytoma and adrenal medulla of the rat.
    Levin RM; Weiss B
    Cancer Res; 1978 Apr; 38(4):915-20. PubMed ID: 205349
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.